{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T08:25:18Z","timestamp":1779179118054,"version":"3.51.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,1,31]],"date-time":"2018-01-31T00:00:00Z","timestamp":1517356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2018,1,31]],"date-time":"2018-01-31T00:00:00Z","timestamp":1517356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Res"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1038\/pr.2017.323","type":"journal-article","created":{"date-parts":[[2017,12,26]],"date-time":"2017-12-26T19:47:18Z","timestamp":1514317638000},"page":"889-896","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Maternal phenylketonuria syndrome: studies in mice suggest a potential approach to a continuing problem"],"prefix":"10.1038","volume":"83","author":[{"given":"William L","family":"Zeile","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen C","family":"McCune","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald G","family":"Musson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"O'Donnell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles A","family":"O'Neill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurie S","family":"Tsuruda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto T","family":"Zori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip J","family":"Laipis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,1,31]]},"reference":[{"key":"BFpr2017323_CR1","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/S0140-6736(10)60961-0","volume":"376","author":"N Blau","year":"2010","unstructured":"Blau N, van Spronsen FJ, Levy HL . Phenylketonuria. Lancet 2010;376:1417\u20131427.","journal-title":"Lancet"},{"key":"BFpr2017323_CR2","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ymgme.2007.05.006","volume":"92","author":"SE Waisbren","year":"2007","unstructured":"Waisbren SE, Noel K, Fahrbach K et al. Phenylalanine blood levels and clinical outcomes in phenylketonuria: a systematic literature review and meta-analysis. Mol Genet Metab 2007;92:63\u201370.","journal-title":"Mol Genet Metab"},{"key":"BFpr2017323_CR3","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/j.1651-2227.1954.tb04000.x","volume":"43","author":"H Bickel","year":"1954","unstructured":"Bickel H, Gerrard J, Hickmans EM . The influence of phenylalanine intake on the chemistry and behaviour of a phenyl-ketonuric child. Acta Paediatr 1954;43:64\u201377.","journal-title":"Acta Paediatr"},{"key":"BFpr2017323_CR4","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/35014676","volume":"405","author":"D Paul","year":"2000","unstructured":"Paul D . A double-edged sword. Nature 2000;405:515.","journal-title":"Nature"},{"key":"BFpr2017323_CR5","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/BF01799519","volume":"13","author":"R Koch","year":"1990","unstructured":"Koch R, Hanley W, Levy H et al. A preliminary report of the collaborative study of maternal phenylketonuria in the United States and Canada. J Inherit Metab Dis 1990;13:641\u2013650.","journal-title":"J Inherit Metab Dis"},{"key":"BFpr2017323_CR6","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/(SICI)1096-8628(19970303)69:1<89::AID-AJMG17>3.0.CO;2-K","volume":"69","author":"B Rouse","year":"1997","unstructured":"Rouse B, Azen C, Koch R et al. Maternal Phenylketonuria Collaborative Study (MPKUCS) offspring: facial anomalies, malformations, and early neurological sequelae. Am J Med Genet 1997;69:89\u201395.","journal-title":"Am J Med Genet"},{"key":"BFpr2017323_CR7","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1023\/A:1005359313883","volume":"21","author":"SE Waisbren","year":"1998","unstructured":"Waisbren SE, Chang P, Levy HL et al. Neonatal neurological assessment of offspring in maternal phenylketonuria. J Inherit Metab Dis 1998;21:39\u201348.","journal-title":"J Inherit Metab Dis"},{"key":"BFpr2017323_CR8","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1542\/peds.112.S4.1544","volume":"112","author":"SE Waisbren","year":"2003","unstructured":"Waisbren SE, Azen C . Cognitive and behavioral development in maternal phenylketonuria offspring. Pediatrics 2003;112:1544\u20131547.","journal-title":"Pediatrics"},{"key":"BFpr2017323_CR9","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1542\/peds.112.S4.1537","volume":"112","author":"KF Widaman","year":"2003","unstructured":"Widaman KF, Azen C . Relation of prenatal phenylalanine exposure to infant and childhood cognitive outcomes: results from the International Maternal PKU Collaborative Study. Pediatrics 2003;112:1537\u20131543.","journal-title":"Pediatrics"},{"key":"BFpr2017323_CR10","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0022-3476(00)90050-7","volume":"136","author":"B Rouse","year":"2000","unstructured":"Rouse B, Matalon R, Koch R et al. Maternal phenylketonuria syndrome: congenital heart defects, microcephaly, and developmental outcomes. J Pediatr 2000;136:57\u201361.","journal-title":"J Pediatr"},{"key":"BFpr2017323_CR11","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ymgme.2010.05.017","volume":"101","author":"GM Enns","year":"2010","unstructured":"Enns GM, Koch R, Brumm V, Blakely E, Suter R, Jurecki E . Suboptimal outcomes in patients with PKU treated early with diet alone: revisiting the evidence. Mol Genet Metab 2010;101:99\u2013109.","journal-title":"Mol Genet Metab"},{"issue":"Suppl 1","key":"BFpr2017323_CR12","doi-asserted-by":"publisher","first-page":"S68","DOI":"10.1016\/j.ymgme.2009.10.014","volume":"99","author":"R Koch","year":"2010","unstructured":"Koch R, Trefz F, Waisbren S . Psychosocial issues and outcomes in maternal PKU. Mol Genet Metab 2010;99 (Suppl 1): S68\u2013S74.","journal-title":"Mol Genet Metab"},{"key":"BFpr2017323_CR13","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1056\/NEJM198011203032104","volume":"303","author":"RR Lenke","year":"1980","unstructured":"Lenke RR, Levy HL . Maternal phenylketonuria and hyperphenylalaninemia. An international survey of the outcome of untreated and treated pregnancies. N Engl J Med 1980;303:1202\u20131208.","journal-title":"N Engl J Med"},{"key":"BFpr2017323_CR14","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1542\/peds.112.S4.1523","volume":"112","author":"R Koch","year":"2003","unstructured":"Koch R, Hanley W, Levy H et al. The Maternal Phenylketonuria International Study (1984\u20132002). Pediatrics 2003;112:1523\u20131529.","journal-title":"Pediatrics"},{"key":"BFpr2017323_CR15","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1006\/mgme.2000.3038","volume":"71","author":"R Koch","year":"2000","unstructured":"Koch R, Hanley W, Levy H et al. Maternal phenylketonuria: an international study. Mol Genet Metab 2000;71:233\u2013239.","journal-title":"Mol Genet Metab"},{"key":"BFpr2017323_CR16","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/j.1749-6632.1986.tb40340.x","volume":"477","author":"R Matalon","year":"1986","unstructured":"Matalon R, Michals K, Gleason L . Maternal PKU: strategies for dietary treatment and monitoring compliance. Ann NY Acad Sci 1986;477:223\u2013230.","journal-title":"Ann NY Acad Sci"},{"key":"BFpr2017323_CR17","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1136\/adc.2003.037762","volume":"90","author":"PJ Lee","year":"2005","unstructured":"Lee PJ, Ridout D, Walter JH, Cockburn F . Maternal phenylketonuria: Report from the United Kingdom Registry 1978\u201397. Arch Dis Child 2005;90:143\u2013146.","journal-title":"Arch Dis Child"},{"key":"BFpr2017323_CR18","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1093\/ajcn\/88.3.700","volume":"88","author":"F Maillot","year":"2008","unstructured":"Maillot F, Lilburn M, Baudin J, Morley DW, Lee PJ . Factors influencing outcomes in the offspring of mothers with phenylketonuria during pregnancy: the importance of variation in maternal blood phenylalanine. Am J Clin Nutr 2008;88:700\u2013705.","journal-title":"Am J Clin Nutr"},{"issue":"Suppl 2","key":"BFpr2017323_CR19","doi-asserted-by":"publisher","first-page":"S142","DOI":"10.1007\/PL00014378","volume":"159","author":"RO Fisch","year":"2000","unstructured":"Fisch RO . Comments on diet and compliance in phenylketonuria. Eur J Pediatr 2000;159 (Suppl 2): S142\u2013S144.","journal-title":"Eur J Pediatr"},{"key":"BFpr2017323_CR20","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.jmb.2008.05.025","volume":"380","author":"L Wang","year":"2008","unstructured":"Wang L, Gamez A, Archer H et al. Structural and biochemical characterization of the therapeutic Anabaena variabilis phenylalanine ammonia lyase. J Mol Biol 2008;380:623\u2013635.","journal-title":"J Mol Biol"},{"key":"BFpr2017323_CR21","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1093\/genetics\/134.4.1205","volume":"134","author":"A Shedlovsky","year":"1993","unstructured":"Shedlovsky A, McDonald JD, Symula D, Dove WF . Mouse models of human phenylketonuria. Genetics 1993;134:1205\u20131210.","journal-title":"Genetics"},{"key":"BFpr2017323_CR22","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1111\/j.1528-1167.2007.01115.x","volume":"48","author":"AE Martynyuk","year":"2007","unstructured":"Martynyuk AE, Ucar DA, Yang DD et al. Epilepsy in phenylketonuria: a complex dependence on serum phenylalanine levels. Epilepsia 2007;48:1143\u20131150.","journal-title":"Epilepsia"},{"key":"BFpr2017323_CR23","doi-asserted-by":"publisher","first-page":"20894","DOI":"10.1073\/pnas.0808421105","volume":"105","author":"CN Sarkissian","year":"2008","unstructured":"Sarkissian CN, G\u00e1mez A, Wang L et al. Preclinical evaluation of multiple species of PEGylated recombinant phenylalanine ammonia lyase for the treatment of phenylketonuria. Proc Natl Acad Sci USA 2008;105:20894\u201320899.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFpr2017323_CR24","first-page":"885","volume":"59","author":"MW McCaman","year":"1962","unstructured":"McCaman MW, Robins E . Fluorimetric method for the determination of phenylalanine in serum. J Lab Clin Med 1962;59:885\u2013890.","journal-title":"J Lab Clin Med"},{"key":"BFpr2017323_CR25","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0009-9120(02)00311-9","volume":"35","author":"KH Schulpis","year":"2002","unstructured":"Schulpis KH, Tjamouranis J, Karikas GA, Michelakakis H, Tsakiris S . In vivo effects of high phenylalanine blood levels on Na+,K+-ATPase, Mg2+-ATPase activities and biogenic amine concentrations in phenylketonuria. Clin Biochem 2002;35:281\u2013285.","journal-title":"Clin Biochem"},{"key":"BFpr2017323_CR26","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0140-6736(13)61841-3","volume":"384","author":"N Longo","year":"2014","unstructured":"Longo N, Harding CO, Burton BK et al. Single-dose, subcutaneous recombinant phenylalanine ammonia lyase conjugated with polyethylene glycol in adult patients with phenylketonuria: an open-label, multicentre, phase 1 dose-escalation trial. Lancet 2014;384:37\u201344.","journal-title":"Lancet"},{"key":"BFpr2017323_CR27","doi-asserted-by":"publisher","first-page":"34760","DOI":"10.1074\/jbc.273.52.34760","volume":"273","author":"R Shiman","year":"1998","unstructured":"Shiman R, Gray DW . Formation and fate of tyrosine. Intracellular partitioning of newly synthesized tyrosine in mammalian liver. J Biol Chem 1998;273:34760\u201334769.","journal-title":"J Biol Chem"},{"key":"BFpr2017323_CR28","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1016\/0092-8674(95)90145-0","volume":"83","author":"Q-Y Zhou","year":"1995","unstructured":"Zhou Q-Y, Palmiter RD . Dopamine-deficient mice are severely hypoactive, adipsic, and aphagic. Cell 1995;83:1197\u20131209.","journal-title":"Cell"},{"key":"BFpr2017323_CR29","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1086\/501372","volume":"78","author":"S Yang","year":"2006","unstructured":"Yang S, Lee YJ, Kim JM et al. A murine model for human sepiapterin-reductase deficiency. Am J Hum Genet. 2006;78:575\u2013587.","journal-title":"Am J Hum Genet."},{"key":"BFpr2017323_CR30","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1016\/j.neuroscience.2009.01.060","volume":"159","author":"SM Miller","year":"2009","unstructured":"Miller SM, Lonstein JS . Dopaminergic projections to the medial preoptic area of postpartum rats. Neuroscience 2009;159:1384\u20131396.","journal-title":"Neuroscience"},{"key":"BFpr2017323_CR31","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.brainres.2008.04.006","volume":"1217","author":"T Pascucci","year":"2008","unstructured":"Pascucci T, Andolina D, Ventura R, Puglisi-Allegra S, Cabib S . Reduced availability of brain amines during critical phases of postnatal development in a genetic mouse model of cognitive delay. Brain Res 2008;1217:232\u2013238.","journal-title":"Brain Res"},{"key":"BFpr2017323_CR32","first-page":"1","volume":"1","author":"D Andolina","year":"2010","unstructured":"Andolina D, Conversi D, Cabib S et al. 5-Hydroxytryptophan during critical postnatal period improves cognitive performances and promotes dendritic spine maturation in genetic mouse model of phenylketonuria. Int J Neuropsychopharmacol 2010;1:1\u201311.","journal-title":"Int J Neuropsychopharmacol"}],"container-title":["Pediatric Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/pr2017323.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/pr2017323","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/pr.2017.323","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/pr2017323.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:04:21Z","timestamp":1684616661000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/pr2017323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,31]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["BFpr2017323"],"URL":"https:\/\/doi.org\/10.1038\/pr.2017.323","relation":{},"ISSN":["0031-3998","1530-0447"],"issn-type":[{"value":"0031-3998","type":"print"},{"value":"1530-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,31]]},"assertion":[{"value":"19 April 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr Laipis has no financial ties to BioMarin Pharmaceutical other than research funding. Dr Zori and McCune are consultants for BioMarin Pharmaceutical, and directed the Phase II and Phase III trials of rAvPAL-PEG in human patients carried out at the UF College of Medicine, also supported by BioMarin Pharmaceutical. They have no further conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}